We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





MeMed Displays Disruptive Technology Award Finalist COVID-19 Severity Test at AACC 2021

By LabMedica International staff writers
Posted on 29 Sep 2021
Print article
Image: The MeMed Key platform (Photo courtesy of MeMed)
Image: The MeMed Key platform (Photo courtesy of MeMed)

MeMed (Haifa, Israel) displayed the MeMed COVID-19 Severity Test, the Disruptive Technology Award finalist, at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo, the largest global scientific conference & tradeshow in the field of laboratory medicine.

MeMed was named a finalist for the American Association of Clinical Chemistry’s (AACC) Disruptive Technology Award for the MeMed COVID-19 Severity test, which stratifies the risk that a patient with COVID-19 will experience severe outcomes. It reads the immune-system in real time to accurately determine whether SARS-CoV-2 patients are likely to have a severe outcome.

MeMed COVID-19 Severity is a pioneering host response technology that measures multiple proteins from a serum sample and applies machine learning to stratify the risk that a patient with COVID-19 will experience severe outcomes. The test runs in 15 minutes on the company’s cutting edge multi-purpose platform, MeMed Key, for quantitative diagnostic immunoassays that opens the way to central lab performance at the point-of-need, using chemiluminescence detection technology. MeMed Key provides accuracy similar to large central lab immunoassay platforms in a miniaturized and point-of-need format. It has a wide dynamic range from single pg/ml to µg/ml, which opens the way to measuring host and pathogen based immunoassays that are currently only measurable at the central lab.

Also on display at the event was MeMed BV, a host-immune response assay that can aid to distinguish between bacterial and viral infections delivering results in 15 minutes from serum. MeMed BV computationally integrates the levels of three host immune proteins into a simple score indicating the likelihood of a bacterial immune response/co-infection versus a viral immune response. Run on the compact MeMed Key, it is the only test for distinguishing bacterial from viral infections that has been validated in multinational, double-blind and external clinical studies.

Related Links:
MeMed 

New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay
New
Biological Indicator Vials
BI-O.K.

Print article
ADLM

Channels

Molecular Diagnostics

view channel
Image: The biomarkers of kidney injury could help lead to the development of safer medications and improve patient outcomes (Photo courtesy of 123RF)

New Biomarkers to Improve Early Detection and Monitoring of Kidney Injury

Drug-induced kidney injury, also known as nephrotoxicity, is a prevalent issue in clinical practice, occurring when specific medications at certain doses cause damage to the kidneys. Nephrotoxicity can... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.